Profile
| Metric | Value |
|---|---|
| Full Name | Sarepta Therapeutics, Inc. |
| Ticker | NASDAQ: SRPT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | sarepta.com |
| Employees | 1,372 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $23.83 | |
| Price, 1D Change | +2.94% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.50 | |
| Revenue | $2B | |
| Revenue, 1Y Change | +52.97% | |
| EPS | $2.34 | |
| EPS, 1Y Change | +140.31% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:6 | |
| Next Split | N/A | N/A |
| Last Ticker Change | AVII | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.34 | |
| EPS Estimate | -$2.07 | |
| EPS Est. Change | -188.33% | |
| Revenue | $1.90B | |
| Revenue Estimate | $2.12B | |
| Revenue Est. Change | +11.46% | |
| Current Price | $23.83 | |
| Price Target | - | $18.00 |
| Price Tgt. Change | - | -24.46% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$6.43 | -$5.80 | +9.79% | |
| $4.02 | $2.34 | -41.82% | |
| -$2.07 | N/A | -188.33% | |
| $2.76 | N/A | +18.05% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.23B | $1.24B | +1.49% | |
| $1.84B | $1.90B | +3.26% | |
| $2.12B | N/A | +11.46% | |
| $1.59B | N/A | -16.57% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -81.13% | |
| Price, 3Y | -79.72% | |
| Market Cap, 1Y | -79.59% | |
| Market Cap, 3Y | -75.84% | |
| Revenue, 1Y | +52.97% | |
| Revenue, 3Y | +170.98% | |
| EPS, 1Y | +140.31% | |
| EPS, 3Y | +145.37% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $23.83 | |
| SMA 200 | $27.74 | |
| SMA 200 vs Price | +16.43% | |
| SMA 50 | $20.64 | |
| SMA 50 vs Price | -13.39% | |
| Beta | 1.50 | |
| ATR | $1.14 | |
| 14-Day RSI | 63.80 | |
| 10-Day Volatility | 45.62% | |
| 1-Year Volatility | 105.33% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $1.90B | |
| EPS | $2.34 | |
| Gross Profit | $1.55B | |
| Gross Margin | 81.24% | |
| Operating Profit | $218.08M | |
| Operating Margin | 11.47% | |
| Net Income | $235.24M | |
| Net Margin | 12.37% | |
| EBITDA | $316.89M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.74 | |
| Current Ratio | 4.20 | |
| Quick Ratio | 3.18 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | 0.55 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 1.03 | |
| PB Ratio | 1.89 | |
| EV/EBITDA | -137.39 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.53B | |
| Cash & Equivalents | $1.10B | |
| Total Assets | $3.96B | |
| Current Assets | $3.07B | |
| Total Liabilities | $2.44B | |
| Current Liabilities | $731.68M | |
| Total Debt | $1.34B | |
| Short Term Debt | $13.27M | |
| Accounts Payable | $214.44M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.68B | |
| Operating Expenses | $1.36B | |
| Cost Of Goods Sold | $356.82M | |
| SG&A | $557.87M | |
| D&A | $37.72M | |
| Interest Expense | $0.00 | |
| Income Tax | $25.54M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$205.79M | |
| CFI | $755.56M | |
| CFF | $124.81M | |
| Capex | $146.96M | |
| Free Cash Flow | -$352.74M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wedbush | ||
| Wells Fargo | → | |
| Mizuho | → | |
| Guggenheim | → | |
| Barclays | → | |
| Baird | → | |
| Piper Sandler | → | |
| BMO Capital | → | |
| Guggenheim | → | |
| Leerink Partners | → |
Analyst sentiment
Institutional ownership
Screeners with SRPT
Data Sources & References
- SRPT Official Website www.sarepta.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/873303/000119312525262591/0001193125-25-262591-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/873303/000095017025029973/0000950170-25-029973-index.htm
- SRPT Profile on Yahoo Finance finance.yahoo.com/quote/SRPT
- SRPT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/srpt
FAQ
What is the ticker symbol for Sarepta Therapeutics, Inc.?
The ticker symbol for Sarepta Therapeutics, Inc. is NASDAQ:SRPT
Does Sarepta Therapeutics, Inc. pay dividends?
No, Sarepta Therapeutics, Inc. does not pay dividends
What sector is Sarepta Therapeutics, Inc. in?
Sarepta Therapeutics, Inc. is in the Healthcare sector
What industry is Sarepta Therapeutics, Inc. in?
Sarepta Therapeutics, Inc. is in the Biotechnology industry
What country is Sarepta Therapeutics, Inc. based in?
Sarepta Therapeutics, Inc. is headquartered in United States
When did Sarepta Therapeutics, Inc. go public?
Sarepta Therapeutics, Inc. initial public offering (IPO) was on June 4, 1997
Is Sarepta Therapeutics, Inc. in the S&P 500?
No, Sarepta Therapeutics, Inc. is not included in the S&P 500 index
Is Sarepta Therapeutics, Inc. in the NASDAQ 100?
No, Sarepta Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Sarepta Therapeutics, Inc. in the Dow Jones?
No, Sarepta Therapeutics, Inc. is not included in the Dow Jones index
When was Sarepta Therapeutics, Inc. last earnings report?
Sarepta Therapeutics, Inc.'s most recent earnings report was on November 3, 2025
When does Sarepta Therapeutics, Inc. report earnings?
The next expected earnings date for Sarepta Therapeutics, Inc. is February 25, 2026